Pro-Gastrin-Releasing-Peptide

Last updated

Pro-Gastrin-Releasing-Peptide, also known as Pro-GRP, is a Gastrin-Releasing-Peptide (GRP) precursor, a neurotransmitter that belongs to the bombesine/neuromedin B family. GRP stimulates the secretion of gastrin in order to increase the acidity of the gastric acid. Pro-GRP is a peptide composed of 125 amino acids, expressed in the nervous system and digestive tract. [1] [2] It is also important to not confused with progastrin, consisting of 80 amino acids, precursor of gastrin in its intracellular version and oncogene in its extracellular version (hPG80). [3] [4]

The presence of GRP in lung cancer samples was identified in 1983. [5] In pathological situations, GRP has mitogenic activity in vitro in many tumors such as pancreatic, small cell lung (SCLC), prostate, kidney, breast and colorectal cancers. [6] [7] [8] [9] GRP could operate as an autocrine growth factor. In cancers, GRP induces cell growth and inhibits apoptosis by shutting down the endoplasmic reticulum stress pathway. [10] The mechanisms of the impacted signal pathways have not been established. [11]   As early as 1994, research on Pro-GRP as a biomarker for small cell lung cancer began. [12] Because of the very short half-life of GRP (2 minutes), the Pro-GRP is used for measurements and analysis. Since then, Pro-GRP has been used as a tumor marker for patients with small cell lung cancer (SCLC) in limited and extended stages. [13]

Related Research Articles

<span class="mw-page-title-main">Zollinger–Ellison syndrome</span> Condition in which tumours stimulate excessive gastric acid production

Zollinger–Ellison syndrome is rare disease in which tumors cause the stomach to produce too much acid, resulting in peptic ulcers. Symptoms include abdominal pain and diarrhea.

<span class="mw-page-title-main">Substance P</span> Chemical compound (polypeptide neurotransmitter)

Substance P (SP) is an undecapeptide and a type of neuropeptide, belonging to the tachykinin family of neuropeptides. It acts as a neurotransmitter and a neuromodulator. Substance P and the closely related neurokinin A (NKA) are produced from a polyprotein precursor after alternative splicing of the preprotachykinin A gene. The deduced amino acid sequence of substance P is as follows:

<span class="mw-page-title-main">Gastrin</span> Mammalian protein found in Homo sapiens

Gastrin is a peptide hormone that stimulates secretion of gastric acid (HCl) by the parietal cells of the stomach and aids in gastric motility. It is released by G cells in the pyloric antrum of the stomach, duodenum, and the pancreas.

Bombesin is a 14-amino acid peptide originally isolated from the skin of the European fire-bellied toad by Vittorio Erspamer et al. and named after its source. It has two known homologs in mammals called neuromedin B and gastrin-releasing peptide. It stimulates gastrin release from G cells. It activates three different G-protein-coupled receptors known as BBR1, -2, and -3. It also activates these receptors in the brain. Together with cholecystokinin, it is the second major source of negative feedback signals that stop eating behaviour.

<span class="mw-page-title-main">Small-cell carcinoma</span> Type of malignant cancer

Small-cell carcinoma is a type of highly malignant cancer that most commonly arises within the lung, although it can occasionally arise in other body sites, such as the cervix, prostate, and gastrointestinal tract. Compared to non-small cell carcinoma, small cell carcinoma is more aggressive, with a shorter doubling time, higher growth fraction, and earlier development of metastases.

Neuroendocrine cells are cells that receive neuronal input and, as a consequence of this input, release messenger molecules (hormones) into the blood. In this way they bring about an integration between the nervous system and the endocrine system, a process known as neuroendocrine integration. An example of a neuroendocrine cell is a cell of the adrenal medulla, which releases adrenaline to the blood. The adrenal medullary cells are controlled by the sympathetic division of the autonomic nervous system. These cells are modified postganglionic neurons. Autonomic nerve fibers lead directly to them from the central nervous system. The adrenal medullary hormones are kept in vesicles much in the same way neurotransmitters are kept in neuronal vesicles. Hormonal effects can last up to ten times longer than those of neurotransmitters. Sympathetic nerve fiber impulses stimulate the release of adrenal medullary hormones. In this way the sympathetic division of the autonomic nervous system and the medullary secretions function together.

<span class="mw-page-title-main">Gastrin-releasing peptide</span>

Gastrin-releasing peptide, also known as GRP, is a neuropeptide, a regulatory molecule that has been implicated in a number of physiological and pathophysiological processes. Most notably, GRP stimulates the release of gastrin from the G cells of the stomach.

<span class="mw-page-title-main">Gastrinoma</span> Medical condition

Gastrinomas are neuroendocrine tumors (NETs), usually located in the duodenum or pancreas, that secrete gastrin and cause a clinical syndrome known as Zollinger–Ellison syndrome (ZES). A large number of gastrinomas develop in the pancreas or duodenum, with near-equal frequency, and approximately 10% arise as primary neoplasms in lymph nodes of the pancreaticoduodenal region.

<span class="mw-page-title-main">Enteroendocrine cell</span>

Enteroendocrine cells are specialized cells of the gastrointestinal tract and pancreas with endocrine function. They produce gastrointestinal hormones or peptides in response to various stimuli and release them into the bloodstream for systemic effect, diffuse them as local messengers, or transmit them to the enteric nervous system to activate nervous responses. Enteroendocrine cells of the intestine are the most numerous endocrine cells of the body. They constitute an enteric endocrine system as a subset of the endocrine system just as the enteric nervous system is a subset of the nervous system. In a sense they are known to act as chemoreceptors, initiating digestive actions and detecting harmful substances and initiating protective responses. Enteroendocrine cells are located in the stomach, in the intestine and in the pancreas. Microbiota play key roles in the intestinal immune and metabolic responses in these enteroendocrine cells via their fermentation product, acetate.

H1299, also known as NCI-H1299 or CRL-5803, is a human non-small cell lung carcinoma cell line derived from the lymph node, which is widely used in research.

<span class="mw-page-title-main">Gastrin-releasing peptide receptor</span> Protein-coding gene in the species Homo sapiens

The gastrin-releasing peptide receptor (GRPR), now properly known as BB2 is a G protein-coupled receptor whose endogenous ligand is gastrin releasing peptide. In humans it is highly expressed in the pancreas and is also expressed in the stomach, adrenal cortex and brain.

Vaccine therapy is a type of treatment that uses a substance or group of substances to stimulate the immune system to destroy a tumor or infectious microorganisms such as bacteria or viruses.

<span class="mw-page-title-main">Combined small-cell lung carcinoma</span> Medical condition

Combined small cell lung carcinoma is a form of multiphasic lung cancer that is diagnosed by a pathologist when a malignant tumor, arising from transformed cells originating in lung tissue, contains a component of;small cell lung carcinoma (SCLC), admixed with one components of any histological variant of non-small cell lung carcinoma (NSCLC) in any relative proportion.

Treatment of lung cancer refers to the use of medical therapies, such as surgery, radiation, chemotherapy, immunotherapy, percutaneous ablation, and palliative care, alone or in combination, in an attempt to cure or lessen the adverse impact of malignant neoplasms originating in lung tissue.

Targeted therapy of lung cancer refers to using agents specifically designed to selectively target molecular pathways responsible for, or that substantially drive, the malignant phenotype of lung cancer cells, and as a consequence of this (relative) selectivity, cause fewer toxic effects on normal cells.

Bombesin-like peptides comprise a large family of peptides which were initially isolated from amphibian skin, where they stimulate smooth muscle contraction. They were later found to be widely distributed in mammalian neural and endocrine cells.

Neuroendocrine differentiation is a term primarily used in relation to prostate cancers that display a significant neuroendocrine cell population on histopathological examination. These types of prostate cancer comprise true neuroendocrine cancers, such as small cell carcinoma, carcinoid and carcinoid-like tumors, as well as prostatic adenocarcinoma exhibiting focal neuroendocrine phenotype.

<span class="mw-page-title-main">Lurbinectedin</span> Chemical compound

Lurbinectedin, sold under the brand name Zepzelca, is a medication used for the treatment of small cell lung cancer.

Progastrin is an 80-amino acid intracellular protein and the precursor of gastrin, a gastrointestinal hormone produced by G cells in the gastric antrum. The main function of gastrin is to regulate acid secretion. During digestion, only gastrin is released into the bloodstream and stimulates the secretion of hydrochloric acid in the stomach as well as pancreatic digestive enzymes. In humans, progastrin is encoded by the GAST gene. Progastrin is expressed primarily in stomach tissue.

hPG80 refers to the extracellular and oncogenic version of progastrin. This name first appeared in a scientific publication in January 2020. Until that date, scientific publications only mention 'progastrin', without necessarily explicitly specifying whether it is intracellular or extracellular in the tumor pathological setting.

References

  1. ↑ Dumesny, Chelsea; Patel, Oneel; Lachal, Shamilah; Giraud, Andrew S.; Baldwin, Graham S.; Shulkes, Arthur (2006). "Synthesis, expression and biological activity of the prohormone for gastrin releasing peptide (ProGRP)". Endocrinology. 147 (1): 502–509. doi: 10.1210/en.2005-0574 . ISSN   0013-7227. PMID   16223866.
  2. ↑ Saurin, Jc; Némoz-Gaillard, E; Ratineau, C; Chayvialle, Ja; Abello, J (2000). "Le neuropeptide bombésine module la prolifération et l'invasion tumorale". Médecine/Sciences. 16 (8–9): 929. doi:10.4267/10608/1760. hdl:10608/1760. ISSN   1958-5381.
  3. ↑ Verena, D. Huebner; Roulan, JiangS; Terry D., Lee; Kassu, Legesse; Takeshi, AzumiQ (April 2, 1990). Purification and Structural Characterization of Progastrin-derived Peptides from a Human Gastrinoma (PDF). THE JOURNAL OF BIOLOGICAL CHEMISTRY.
  4. ↑ You, Benoit; Mercier, Frédéric; Assenat, Eric; Langlois-Jacques, Carole; Glehen, Olivier; Soulé, Julien; Payen, Léa; Kepenekian, Vahan; Dupuy, Marie; Belouin, Fanny; Morency, Eric (2020). "The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients". EBioMedicine. 51: 102574. doi:10.1016/j.ebiom.2019.11.035. PMC   6938867 . PMID   31877416.
  5. ↑ Bhatnagar, M.; Springall, D. R.; Ghatei, M. A.; Burnet, P. W. J.; Hamid, Q.; Giaid, A.; Ibrahim, N. B. N.; Cuttitta, F.; Spindel, E. R.; Penketh, R.; Rodek, C. (1988-07-01). "Localisation of mRNA and co-expression and molecular forms of GRP gene products in endocrine cells of fetal human lung". Histochemistry. 90 (4): 299–307. doi:10.1007/BF00495974. ISSN   0301-5564. PMID   3068217. S2CID   12060289.
  6. ↑ Uchida, Kazuhiro; Kojima, Akira; Morokawa, Nasa; Tanabe, Osamu; Anzai, Chieko; Kawakami, Makio; Eto, Yoshikatsu; Yoshimura, Kunihiko (2002-12-01). "Expression of progastrin-releasing peptide and gastrin-releasing peptide receptor mRNA transcripts in tumor cells of patients with small cell lung cancer". Journal of Cancer Research and Clinical Oncology. 128 (12): 633–640. doi:10.1007/s00432-002-0392-8. ISSN   0171-5216. PMID   12474049. S2CID   23764903.
  7. ↑ Preston, Shaun R.; Miller, Glenn V.; Primrose, John N. (1996). "Bombesin-like peptides and cancer". Critical Reviews in Oncology/Hematology. 23 (3): 225–238. doi:10.1016/1040-8428(96)00204-1. PMID   8842591.
  8. ↑ Moody, Terry W.; Chan, Daniel; Jensen, Jan Fahrenkrug and Robert T. (2003-01-31). "Neuropeptides as Autocrine Growth Factors in Cancer Cells". Current Pharmaceutical Design. 9 (6): 495–509. doi:10.2174/1381612033391621. PMID   12570813 . Retrieved 2020-08-03.
  9. ↑ Patel, Oneel; Dumesny, Chelsea; Giraud, Andrew S.; Baldwin, Graham S.; Shulkes, Arthur (2004). "Stimulation of proliferation and migration of a colorectal cancer cell line by amidated and glycine-extended gastrin-releasing peptide via the same receptor". Biochemical Pharmacology. 68 (11): 2129–2142. doi:10.1016/j.bcp.2004.08.009. PMID   15498503.
  10. ↑ Li, Xinqiu; Zhang, Litang; Ke, Xianzhu; Wang, Yuming (2013). "Human gastrin-releasing peptide triggers growth of HepG2 cells through blocking endoplasmic reticulum stress-mediated apoptosis". Biochemistry (Moscow). 78 (1): 102–110. doi:10.1134/S0006297913010136. ISSN   0006-2979. PMID   23379566. S2CID   18293652.
  11. ↑ "Gastrin-releasing peptide gene-associated peptides are expressed in normal human fetal lung and small cell lung cancer: A novel peptide family found in man". Lung Cancer. 5: 10. 1989. doi:10.1016/0169-5002(89)90319-x. ISSN   0169-5002.
  12. ↑ "Pro-gastrin-releasing peptide (PROGRP) as a specific tumor marker in patients with small cell lung carcinoma (SCLC)". Lung Cancer. 11: 45. 1994. doi:10.1016/0169-5002(94)93944-6. ISSN   0169-5002.
  13. ↑ Cavalieri, Stefano; Morelli, Daniele; Martinetti, Antonia; Galli, Giulia; Nichetti, Federico; de Braud, Filippo; Platania, Marco (2018). "Clinical implications for pro-GRP in small cell lung cancer. A single center experience". The International Journal of Biological Markers. 33 (1): 55–61. doi: 10.5301/ijbm.5000305 . hdl: 2434/551868 . ISSN   1724-6008. PMID   28967066.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.